ClinicalTrials.gg
CompletedNCT02034708REMINDUpdated Dec 30, 2016Results posted

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

A Phase 4 interventional study of Dotarem® and Gadovist®/Gadavist® in Primary Brain Tumor, sponsored by Guerbet. Completed at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-30.

Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,443 studies in Brain Neoplasms with a site in United States — 230 open to participants now, 351 under way, 18 of them phase 3. Brain Neoplasms · United States.

Enrollment
48th of 1,188
279 · median 30
Started
2014
with 53 others
Phase 4
18 of 1,443
4 open now
Registered
750th of 1,443
by date

Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 48th largest by enrollment of the 1,188 interventional ones that give a count, is one of 54 that started in 2014, is one of 18 in phase 4, and was the 750th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

230 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

225 more — sign in →

All 230 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,443 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization (off-site assessment).

270 patients will be randomized between 2 arms defining the sequence of administration of the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14 days in between.

Each patient will, therefore, receive two MRI during his/her participation in the study.

The two arms consist in :

  • Dotarem® in the first MRI, then Gadovist®/Gadavist® in the second MRI.
  • Gadovist®/Gadavist® in the first MRI, then Dotarem® in the second MRI.

Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems.

MRI examinations will be evaluated centrally by blinded independent readers for the main evaluation criterion.

03

Conditions studied

  • Primary Brain Tumor

Browse trials for

Keywords

  • Primary brain tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male adult patient (patient having reached legal majority age)
  • Patient with known or highly suspected primary intracranial tumors (intra-axial or extra-axial) detected by previous CT or MRI examination who are scheduled to undergo a routine contrast-enhanced MRI
  • Female patient must have effective throughout the study and must have a negative urine pregnancy test at inclusion, or be surgically sterilized, or (minimum 12 months of amenorrhea)
  • Patient having provided his/her written to participate in the trial prior to any study-related procedure being conducted
  • Patient with national health insurance (according to local regulatory requirements)

Exclusion criteria

Exclusion Criteria:

  • Patient with rapidly evolving brain tumor that could change in appearance between the time of the two study MRI examinations.
  • Patient undergoing current or recent treatment within past 6 weeks or scheduled for any treatment that could results in changes of lesion appearance between the two study examinations. This would include, but not restricted to, the following: current or recent radiation therapy, surgery, starting or recent chemotherapy.
  • Patient with a to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, infusion pumps, cochlear implants metallic or others according to the imaging site standard practice)
  • Patient with known severely impaired renal function (defined as MDRD\< 30 ml/min/1.73m2)
  • Patient with known Class III/IV congestive heart failure according to the classification
  • Patient with known severe adverse drug reaction or contraindication to Gadolinium-Based Contrast Agent
  • Patient having received any contrast agent within 48 hours prior to first study contrast agent injection scheduled for the study and patient expected to receive any other contrast agent within 24 hours of the last study contrast agent injection
  • Patient presenting with any condition which, based on the investigator's clinical judgment, would prevent the patient from completing all trial assessments and visits
  • Patient under guardianship and/or unable or unwilling to cooperate with the requirements of this trial
  • Pregnant or breast feeding female patient
  • Patient already included in this trial
  • Patient included in another clinical trial involving an IMP within 30 days before the first contrast agent injection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Dotarem®/Gadovist®

    Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI

    Drug: Dotarem® · Drug: Gadovist®/Gadavist®

  • Experimental
    Gadovist®/Dotarem®

    Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI

    Drug: Dotarem® · Drug: Gadovist®/Gadavist®

Interventions

  • Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.

  • DrugGadovist®/Gadavist®

    Drug page: Gadobutrol

    Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent

    Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale: 0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.

    Time frame: Up to 15 days after randomization

07

Results

Posted Oct 25, 2016

Participant flow

Adult patients with known or highly suspected primary intracranial tumors and scheduled for a Dotarem®-enhanced MRI were recruited in 27 active centers in 4 countries (Colombia, South Korea, Mexico and United States) from June 2014 to September 2015.

First Contrast Agent Injection (1 Day)
Participant flow — First Contrast Agent Injection (1 Day)
MilestoneDotarem®/Gadovist®Gadovist®/Dotarem®
Started138130
Completed138130
Not completed00
Wash-out (From 2 Days up to 14 Days)
Participant flow — Wash-out (From 2 Days up to 14 Days)
MilestoneDotarem®/Gadovist®Gadovist®/Dotarem®
Started138130
Completed129120
Not completed910
Withdrew: Withdrawal by subject25
Withdrew: Adverse event10
Withdrew: Protocol violation33
Withdrew: Other reason32
Second Contrast Agent Injection (1 Day)
Participant flow — Second Contrast Agent Injection (1 Day)
MilestoneDotarem®/Gadovist®Gadovist®/Dotarem®
Started129120
Completed129120
Not completed00

Outcome measures

PrimaryPercentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent

Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale: 0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.

Time frame:
Up to 15 days after randomization
Reported as:
Number · percentage of patients
Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent
percentage of patientsGadovist® (Reader 1)Dotarem® (Reader 1)Gadovist® (Reader 2)Dotarem® (Reader 2)Gadovist® (Reader 3)Dotarem® (Reader 3)
Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent94.096.293.290.699.6100.0

Adverse events

Collected over From patient inclusion up to 30 min after last contrast agent injection. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dotarem®—1/258 (0.4%)42/258 (16.3%)
Gadovist®—0/259 (0%)44/259 (17%)
Total—1/268 (0.4%)63/268 (23.5%)
Most frequent serious events
Most frequent serious events
EventDotarem®Gadovist®Total
Aggravation of existing disorderGeneral disorders1/2580/2591/268
ComaNervous system disorders1/2580/2591/268
Most frequent other events
Showing 10 of 30
Most frequent other events
EventDotarem®Gadovist®Total
Injection site painGeneral disorders12/25812/25920/268
Medical device painGeneral disorders15/25817/25917/268
HeadacheNervous system disorders4/2583/2597/268
DizzinessNervous system disorders2/2584/2595/268
NauseaGastrointestinal disorders2/2583/2595/268
Injection site paraesthesiaGeneral disorders2/2581/2592/268
ParaesthesiaNervous system disorders2/2580/2592/268
Blood pressure increasedInvestigations0/2582/2592/268
Injection site coldnessGeneral disorders1/2581/2592/268
Musculoskeletal painMusculoskeletal and connective tissue disorders1/2581/2592/268

Baseline characteristics

All patients receiving at least one injection of contrast agent and with one valid assessment of the primary outcome

Age, Continuous
Age, Continuous(years)Dotarem®/Gadovist®Gadovist®/Dotarem®Total
Mean52.9 ± 15.254.4 ± 15.153.6 ± 15.1
Gender
Gender(Participants)Dotarem®/Gadovist®Gadovist®/Dotarem®Total
Female8785172
Male514596
Region of Enrollment
Region of Enrollment(participants)Dotarem®/Gadovist®Gadovist®/Dotarem®Total
Colombia161632
United States464086
Korea, Republic of242347
Mexico5251103
Body Mass Index
Body Mass Index(kg per square metre)Dotarem®/Gadovist®Gadovist®/Dotarem®Total
Mean27.71 ± 5.3527.62 ± 5.2327.66 ± 5.28
08

Study locations

32 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama, United States
  • University of Arizona Medical Center
    Tucson, Arizona AZ 85724, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California, United States
  • Yale University School Of Medicine
    New Haven, Connecticut, United States
  • Infinity Clinical Research, LLC
    Hollywood, Florida FL 33021, United States
  • University of Michigan Health System
    Ann Arbor, Michigan, United States
  • Quest Research Institute
    Farmington Hills, Michigan, United States
  • Spectrum Health
    Grand Rapids, Michigan, United States
  • Washington University
    St. Louis, Missouri, United States
  • Winthrop University Hospital Clinical Trials Center
    Mineola, New York NY 11501, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania, United States
  • MUSC (Medical University of South Carolina)
    Charleston, South Carolina, United States
  • UVM MRI Center for Biomedical Imaging
    Burlington, Vermont, United States
  • University of Washington Medical Center
    Seattle, Washington, United States
  • Fundacion Abood Shaio
    Bogota, Colombia
  • Fundacion Cardioinfantil Instituto de Cardiologia
    Bogota, Colombia
  • Instituto Nacional de Cancerologia
    Bogota, Colombia
  • Centro Medico Imbanaco
    Cali, Colombia
  • Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM
    Medellin, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, Colombia
  • Chungbuk National University
    Cheongju-si, Chungcheongbuk-do 361-711, Korea, Republic of
  • Chonbuk national Univ Hosp
    Jeonju-si, Jeollabuk-do 561-712, Korea, Republic of
  • Seoul St.Mary Hospital
    Seoul, Seocho-gu 137-701, Korea, Republic of
  • Asan medical center
    Seoul, Songpa-Gu 138-736, Korea, Republic of
  • Ajou University Hospital
    Suwon, Korea, Republic of
  • Morales Vargas Centro de Investigación S.C.
    Leon, Guanajuato 37000, Mexico
  • Centro Neurologico ABC
    Mexico, Mexico Distrito Federal 5300, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo Leon 64020, Mexico
  • Winsett Rethman S.A. de C.V.
    Monterrey, Nuevo León, Mexico
  • Hospital CIMA
    Chihuahua, 31238, Mexico
  • Centro Regiomontano de Investigacion S.C.
    Monterrey, Mexico
  • Clinical Research Institute S.C.
    Tlanepantla, Mexico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2014
First posted
Jan 13, 2014
Start
Jun 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Oct 25, 2016
Last update
Dec 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02034708
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Jun 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Oct 25, 2016
Last update
Dec 30, 2016

Study contacts

Kenneth Maravilla, MD
study chair · University of Washington Medical Center, Seattle, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gadoterate meglumine · Gadobutrol

Start the discussion